🔗 Share this article

Given that the US continues making unprecedented revisions to its vaccine schedules, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by expressing skepticism about COVID-19 vaccines throughout the pandemic and has focused upon alleged deaths following Covid vaccination in her short time at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Program

Public health authorities were set to announce radical changes to the childhood vaccine schedule in December, bringing the US with the Danish vaccine program, according to reports – a major change that would put the US out of step with much of the global community with insufficient data for benefit. The announcement has been delayed until the coming year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to present at the event. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to head the division this year.

A Shift at the FDA

This interim role may indicate a strengthened alliance between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the agency – and it signals a renewed priority upon reevaluating already-approved vaccines at the FDA.

The new acting director has repeatedly called for ending specific pediatric shot schedules in the US so as to align more in line with Denmark, a country with nationalized medicine and a citizenry approximately the population of the state of Wisconsin.

To date comments, she has continued to focus on immunizations – typically the responsibility of Prasad, head of the FDA’s vaccine center – rather than medication approval.

Concerns Over Expertise

The appointee has little discernible background in drug development, regulation or leadership, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and CBER since March.

“It seems she lacks to have the requisite experience” for leading the drug-regulation department, stated Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a sizeable institution. She is not an expert in drug approvals.”

Former commissioners of CBER would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that prior appointees who headed CBER have had.”

The drug center has an vast range of responsibilities at the FDA, she stated.

“Everybody just focuses on the innovative therapies, but the generic program authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and other areas, and every single one must be managed,” Dr. Woodcock explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a substantial leadership element to the job, which supervises in excess of 5,000 staff members. “It’s a enormous leadership role, if you perform it correctly,” the former official added.

Official Statement and Disputed Initiatives

In response to concerns about Dr. Høeg's credentials and whether this appointment indicates greater collaboration among agency officials on immunizations, a press secretary said that the “inquiries rely on flawed assumptions”.

“Her experience aligns with the duties of her position,” the representative explained, noting the period Høeg spent guiding the agency head on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial fast-track approval initiative, a controversial expedited medication authorization process that reportedly concerned her former heads. “How are these drugs being picked for this voucher program? Who makes the calls?” Howard asked. “There is a lot of confidentiality occurring at the FDA right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards laxer oversight of most medications, with the exception of vaccines.”

Public History on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if concerning, history, Howard have noted. She authored a study using unconfirmed public submissions to estimate the rate of heart inflammation after COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the incoming federal leadership featured changing regulations for recently developed shots and ending “non-essential” immunizations, she stated post-election on a audio program. At the FDA, Dr. Høeg has reportedly floated the idea of excluding young men from obtaining Covid vaccinations.

“She is an all-around dogmatist who commences with her conclusions and works backwards to fit the evidence in a extremely disingenuous, dishonest manner,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined other skeptics, {like|